The estimated Net Worth of Talent Investments Ltd Equal is at least $3.63 Million dollars as of 11 June 2020. Talent Equal owns over 1,454,545 units of Kezar Life Sciences Inc stock worth over $3,627,636 and over the last 4 years Talent sold KZR stock worth over $0.
Talent has made over 1 trades of the Kezar Life Sciences Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently Talent bought 1,454,545 units of KZR stock worth $7,999,998 on 11 June 2020.
The largest trade Talent's ever made was buying 1,454,545 units of Kezar Life Sciences Inc stock on 11 June 2020 worth over $7,999,998. On average, Talent trades about 1,454,545 units every 0 days since 2020. As of 11 June 2020 Talent still owns at least 6,254,545 units of Kezar Life Sciences Inc stock.
You can see the complete history of Talent Equal stock trades at the bottom of the page.
Talent's mailing address filed with the SEC is 2ND FLOOR, LE PRINCE DE GALLES, 3-5 AVENUE DES CITRONNIERS, MONACO, O9, 98000.
Over the last 6 years, insiders at Kezar Life Sciences Inc have traded over $3,836,099 worth of Kezar Life Sciences Inc stock and bought 6,372,267 units worth $30,891,130 . The most active insiders traders include Venture Investments Ltd Mor..., Asset Management, Lp Chen B..., and Franklin M Berger. On average, Kezar Life Sciences Inc executives and independent directors trade stock every 49 days with the average trade being worth of $91,954. The most recent stock trade was executed by Mark C. Schiller on 2 July 2024, trading 6,688 units of KZR stock currently worth $3,879.
kezar life sciences, inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the united states. the company's lead product candidate is kzr-616, a selective immunoproteasome inhibitor that is in phase 2 clinical trials across five autoimmune indications, including lupus nephritis, autoimmune hemolytic anemia, immune thrombocytopenia, dermatomyositis, and polymyositis; and phase 1b/2 clinical trials in systemic lupus erythematosus and lupus nephritis. its preclinical products include kzr-616, a selective immunoproteasome inhibitor for the treatment of various autoimmune disease indications; and kzr-tbd for the treatment of oncology and autoimmunity. the company was founded in 2015 and is headquartered in south san francisco, california.
Kezar Life Sciences Inc executives and other stock owners filed with the SEC include: